Updates are available Correction dated 2024-07-22
Click to view Correction: https://doi.org/10.1038/s41386-024-01916-0
-
Authors
Kaldewaij, Reinoud https://orcid.org/0000-0003-2177-7380
Salamone, Paula C.
Enmalm, Adam
Östman, Lars
Pietrzak, Michal
Karlsson, Hanna
Löfberg, Andreas
Gauffin, Emelie
Samuelsson, Martin
Gustavson, Sarah
Capusan, Andrea J. https://orcid.org/0000-0003-1758-2206
Olausson, Håkan https://orcid.org/0000-0002-6319-1786
Heilig, Markus
Boehme, Rebecca https://orcid.org/0000-0003-2803-3069
-
Funding
Funding for this research was provided by:
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (019.211SG.005)
Vetenskapsrådet (2019-01873)
- License Information
-
More Information
Article History
Received: 19 January 2024
Revised: 7 June 2024
Accepted: 14 June 2024
First Online: 25 June 2024
Change Date: 22 July 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41386-024-01916-0
Competing interests
: MH has received research funding or consulting fees in the past 5 years from Aelis Farma, Brainsway Technologies, Camurus, Indivior, Janssen, Molteni, Nordic Drugs and Pfizer, and he is an Associate Editor of Neuropsychopharmacology. AJC has received consultancy and speakers’ fees from Indivior, Camurus, Nordic Drugs and DNE Pharma all outside the scope of this work. All remaining authors have no competing interests.
